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Summary
 
Toll-like receptor 4 (TLR4) is a mammalian homologue of 
 
Drosophila
 
 Toll, a leucine-rich re-
peat molecule that can trigger innate responses against pathogens. The TLR4 gene has recently
been shown to be mutated in C3H/HeJ and C57BL/10ScCr mice, both of which are low re-
sponders to lipopolysaccharide (LPS). TLR4 may be a long-sought receptor for LPS. However,
transfection of TLR4 does not confer LPS responsiveness on a recipient cell line, suggesting a
requirement for an additional molecule. Here, we report that a novel molecule, MD-2, is req-
uisite for LPS signaling of TLR4. MD-2 is physically associated with TLR4 on the cell surface
and confers responsiveness to LPS. MD-2 is thus a link between TLR4 and LPS signaling.
Identification of this new receptor complex has potential implications for understanding host
defense, as well as pathophysiologic, mechanisms.
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xclusion of invading nonself pathogens is one of the
basic homeostatic mechanisms for multicellular organ-
isms. In organisms as divergent as plants, flies, and humans,
leucine-rich repeat (LRR)
 
1
 
 molecules have been implicated
in the defense system against pathogens (1–5). LRR, a pro-
tein motif that has been implicated in protein–protein in-
teraction (6), is thought to directly recognize a pathogen or
its products. Toll, a 
 
Drosophila
 
 receptor molecule with ex-
tracellular LRR, has a role in triggering innate defenses
against bacteria or fungi (2). Human homologues were re-
cently cloned and constitute the Toll-like receptor (TLR)
family, in which five TLRs (TLR1 to TLR5) have so far
been isolated (7–9). TLRs are similar to 
 
Drosophila
 
 Toll in
that they have extracellular domains containing LRR and
cytoplasmic portions homologous to the intracellular sig-
naling domain of the type 1 IL-1 receptor. The extracellu-
lar LRR domains are expected to recognize products from
pathogens, and the cytoplasmic domains trigger activation
of the transcription factor nuclear factor (NF)-
 
k
 
B, leading
to the induction of a number of proinflammatory genes.
Recent reports showed that TLR2 and TLR4 may recog-
nize and signal LPS, a constituent of the outer membrane
of the cell walls of gram-negative bacteria. Transfection of
cell lines with TLR2 confers on them the ability to respond
to LPS with activation of NF-
 
k
 
B (10, 11). The TLR4 gene
is defective in C3H/HeJ and C57BL/10ScCr mice, both of
which have been well characterized as hyporesponders to
LPS (12, 13). TLR4, as well as TLR2, may be a long-sought
receptor for LPS (14). However, contrary to this predic-
tion, transfection of cell lines with TLR4 did not confer
the ability to respond to LPS but constitutively activated
NF-
 
k
 
B (11). These studies imply a lack of a factor or a sub-
unit in transfected cells that is indispensable for LPS signal-
ing via TLR4, as suggested by Wright (14). In this study,
we described a novel molecule, designated as MD-2, that is
associated with TLR4 and requisite for its LPS signaling.
 
Materials and Methods
 
Cells and Reagents.
 
An expression plasmid, pEFBOS (15), and
p55Ig
 
k
 
Luc, a reporter construct with three tandemly repeated 
 
k
 
B
motifs upstream of a minimal IFN-
 
b
 
 promoter (16), were gifts
from Drs. Shigekazu Nagata (Osaka University Medical School,
Osaka, Japan) and Takashi Fujita (Tokyo Metropolitan Institute
of Medical Science, Tokyo, Japan), respectively. The human kid-
ney cell line 293T was provided by Dr. T. Hirano (Osaka Uni-
versity Medical School, Osaka, Japan). LPS and lipid A were pur-
chased from Sigma Chemical Co. The rat mAb against mouse
CD14 (17) was provided by Dr. Shunsuke Yamamoto (Oita Med-
ical University, Oita, Japan). An mAb against the flag epitope M2
was purchased from Sigma Chemical Co., and a rat mAb against
the protein C epitope was established in our own laboratory.
 
R. Shimazu and S. Akashi contributed equally to this study.
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Abbreviations used in this paper:
 
 GAPDH, glyceraldehyde-3-phosphate de-
hydrogenase;
 
 
 
LRR, leucine-rich repeat; NF, nuclear factor; RT, reverse
transcriptase; TLR, Toll-like receptor. 
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cDNA Cloning and Sequencing.
 
The Est clone encoding human
MD-2 (sequence data available from EMBL/GenBank/DDBJ
under accession no. AA099571) was purchased from Genome
Systems, Inc. Sequencing was conducted with an ALFexpress DNA
sequencer and a Thermo Sequenase cycle sequencing kit (Amer-
sham Pharmacia Biotech, Ltd.).
 
Northern Hybridization.
 
Total RNA was extracted from vari-
ous cell lines or tissues with Isogen (Nippon Gene) and subjected
to agarose electrophoresis (20 
 
m
 
g/lane). After transfer to a sheet
of nylon membrane (Hybond N
 
1
 
; Amersham Pharmacia Bio-
tech, Ltd.), RNA was hybridized to a probe that had been labeled
by random priming of a cDNA clone. The hybridization buffer
consisted of 10% dextran sulfate (Pharmacia Biotech), 1 M NaCl,
1% SDS, and 50 mM Tris/HCl, pH 7.5. Hybridization was con-
ducted at 65
 
8
 
C for 20 h. Washing was carried out in 2
 
3
 
 SSC and
0.1% SDS at 65
 
8
 
C. Radioactive signals were visualized with an
image analyzer (BAS2000; Fuji Film Co., Ltd.). The same mem-
brane was reprobed for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as an internal control.
 
Stable Transfectants.
 
The IL-3–dependent line Ba/F3 (18) was
transfected with the pEFBOS expression vector encoding human
TLR4. Expression of TLR4 was confirmed by intracellular stain-
ing for the flag epitope, which had been attached to the COOH
terminus of TLR4. The established line was then transfected with
the p55
 
k
 
B reporter construct for measuring NF-
 
k
 
B activity with
luciferase activity (16). Cell lines expressing TLR4 and the reporter
construct were screened by measuring spontaneous luciferase activ-
ity, which was expected to be high due to TLR4 expression (11,
19). One of the selected lines was further transfected with the
expression vector encoding human MD-2 with either the flag
epitope or another epitope tag, protein C (Boehringer Mannheim)
at the COOH terminus. Cells expressing human MD-2 on the cell
surface were screened by staining corresponding epitope tags. We
also transfected human MD-2 with the flag epitope into the origi-
nal Ba/F3 line, and transfectants expressing MD-2 were selected by
permeabilized cell staining of the flag epitope.
 
Surface and Permeabilized Cell Staining.
 
Cells were incubated
with indicated mAbs. After washes with staining buffer (PBS
containing 2% FCS and 0.1% azide), goat anti–mouse IgG–FITC
(Chemicon International, Inc.) or goat anti–rat IgG–PE (South-
ern Biotechnology Associates, Inc.) was added. Propidium iodide
was included in the second incubation to exclude dead cells.
Cells were analyzed on a FACScan™ (Becton Dickinson). Per-
meabilized cell staining was conducted as described by Veis et al.
(20). In brief, staining was conducted with the staining buffer
containing saponin detergent (0.03%; Sigma Chemical Co.).
 
Confocal Microscopy.
 
The transfectant line expressing TLR4
and MD-2 was stained as above with the mouse anti–human
TLR4 mAb and the rat anti–protein C mAb, which recognized
MD-2. The second Abs were goat anti–mouse IgG–FITC for the
HTA125 mAb and goat anti–rat IgG–PE for the anti-protein C
mAb. These second reagents did not react with the other first re-
agent, as judged on a FACScan™ (data not shown). Stained cells
were viewed on a scanning confocal microscope system, Fluoview
(Olympus Corp.).
 
Immunoprecipitation.
 
Cells were washed and lysed in lysis
buffer consisting of 50 mM Tris/HCl, pH 7.5, 150 mM NaCl,
1% Triton X-100, 50 mM iodoacetamide, 1mM PMSF, 10 
 
m
 
g/
ml soybean trypsin inhibitor, 2 mM MgCl
 
2
 
, and 2 mM CaCl
 
2
 
.
After 30-min incubation on ice, lysate was centrifuged and nuclei
were removed. The 
 
N
 
-hydroxysuccinimide-activated Sepharose
4FF beads (Amersham Pharmacia Biotech, Ltd.) coupled with
HTA125 (4 mg/ml) were added to cell lysate and rotated for 2 h
 
at 4
 
8
 
C. Beads were washed in the lysis buffer, and bound proteins
were subjected to SDS-PAGE (9% acrylamide under the nonre-
duced condition) and Western blot analysis. TLR4 and MD-2 were
detected with the anti-flag mAb, M2 (Sigma Chemical Co.) and
Supersignal
 
®
 
 chemiluminescent substrate (Pierce Chemical Co.).
 
Transient Transfection.
 
Transient transfection was conducted
according to the report by Kaisho et al. (21). The human kidney
cell line 293T was plated onto a 24-well plate at 1.5 
 
3
 
 10
 
5 
 
cells/
well on the day before transfection. DNA was diluted in 100 
 
m
 
l
deionized water, and 2 M calcium chloride (14 
 
m
 
l) was added to
DNA. An equal amount (114 
 
m
 
l) of 2
 
3
 
 Hepes-buffered saline
(280 mM NaCl, 50 mM Hepes, and 1.5 mM sodium phosphate,
pH 7.05) was added slowly in a dropwise manner. After 30-min
incubation at room temperature, coprecipitates were added to
293T cells. Medium was changed on the following day, and the
cells were cultured for another day. Cells were harvested with
PBS containing 1 mM EDTA and used for luciferase assays.
 
Luciferase Assay.
 
In transient transfection, the pEFBOS expres-
sion vector encoding 
 
b
 
-galactosidase (a gift from Dr. Masato
Ogata, Osaka University Medical School, Osaka, Japan) was used
as an internal control for transfection. After transient transfection,
cells were lysed in 50 
 
m
 
l lysis buffer, and luciferase activity was
measured using 10 
 
m
 
l lysate and 50 
 
m
 
l luciferase substrate (Nip-
pon Gene). The luminescence was quantitated by a luminometer
(Berthold Japan). Luciferase activity was normalized with the
 
b
 
-galactosidase activity, which was measured with 2-nitro-phenyl-
 
b
 
-
 
d
 
-galactopyranoside (Boehringer Mannheim).
Stable transfectants were inoculated onto 48-well plates (2 
 
3
 
10
 
5
 
/well). LPS and lipid A were added together. After 4 h of
stimulation, cells were harvested and lysed in 50 
 
m
 
l lysis buffer,
and luciferase activity was measured as above.
 
The Anti-TLR4 mAb HTA125.
 
BALB/c mice were immu-
nized with the Ba/F3 line expressing TLR4, and spleen cells
were fused with SP2/0 myeloma cells. An mAb was chosen that
stained the line used for immunization. A more detailed descrip-
tion of the mAbs and expression/function of TLR4 will be pub-
lished elsewhere.
 
Results and Discussion
 
RP105 was cloned in our laboratory as the first LRR mol-
ecule expressed on lymphocytes, the extracellular LRR of
which had similarity to 
 
Drosophila
 
 Toll (22, 23). We have
recently isolated MD-1 as a molecule that is physically asso-
ciated with RP105 on the cell surface (24). MD-1 itself is a
secretory molecule but tethered to the cell surface by coex-
pressed RP105. MD-1 is likely to interact with LRR of
RP105, which constitutes an entire region of the extracel-
lular portion of RP105. As the extracellular LRR of
RP105 is similar to 
 
Drosophila
 
 Toll or homologous TLRs,
we hypothesized that TLRs might also be associated with a
molecule like MD-1. The hypothesis prompted us to seek
a molecule with similarity to MD-1. A computer search us-
ing the MD-1 amino acid sequence retrieved a human
cDNA clone from an expressed sequence tag database (Se-
quence data available from EMBL/GenBank/DDBJ under
accession no. AA099571). The whole nucleotide sequence
was determined and is shown in Fig. 1 A. After an in-frame
stop codon, the longest open reading frame codes for 160
amino acids, including a 16-residue, NH
 
2
 
-terminal hydro-
phobic stretch that may function as a signal peptide. We re- 
1779
 
Shimazu et al.
 
fer to a mature molecule as MD-2. Significant similarity
(23% identity) to MD-1 was observed over the mature
polypeptide (Fig. 1 B). Notably, five out of seven cysteines
of MD-2 are shared by MD-1. Expression of the MD-2
transcript was examined with Northern hybridization (Fig.
2). The size of the transcript was 
 
z
 
0.7 kb, which is consis-
tent with the size of the cDNA clone. The transcript was
demonstrable in all human lines studied (Fig. 2 A). Three B
lymphoma cell lines (Nalm-6, Daudi, and RPMI8866)
showed relatively high expression. We also studied distri-
bution of the MD-2 transcript in mouse tissues, using the
mouse MD-2 probe that was cloned in our laboratory (Shi-
mazu, R., and K. Miyake, unpublished data). Mouse MD-2
was similar to a human homologue in the size of mRNA.
The transcript was also ubiquitously observed in all mouse
tissues examined, among which spleen and kidney showed
pronounced expression (Fig. 2 B).
We then studied interaction of MD-2 and RP105 or
TLRs. RP105 seemed unlikely to interact with MD-2, as
transfection of MD-2 with RP105, contrary to the case
with MD-1, did not result in cell surface expression of
MD-2 (data not shown). We next studied interaction with
TLRs, among which TLR4 is of particular interest, be-
cause it most resembled RP105 in the extracellular LRR
domain, and cells expressing the TLR4 transcript were also
positive for MD-2 mRNA (Fig. 2 A). The expression vec-
tor encoding MD-2 was transfected into the Ba/F3 line.
Although the precursor was demonstrable inside the cell
(Fig. 3 d), MD-2 was not detectable on the cell surface (Fig.
3 a). In sharp contrast, MD-2 appears on the cell surface in a
stable line expressing TLR4 (Fig. 3 c) as well as MD-2 (Fig.
3 b) and seemed to be colocalized with TLR4 on a scanning
confocal microscope (data not shown). These results are
consistent with membrane anchoring of MD-2 via physical
association with TLR4.
To confirm the association, immunoprecipitation exper-
iments were conducted using the transfectants expressing
TLR4 and MD-2 with the newly made mAb to TLR4
(HTA125; see Materials and Methods). It should be noted
that the HTA125 mAb was established by immunizing cells
expressing TLR4 alone and recognizes TLR4 but not
MD-2 (Fig. 4 A). Coprecipitation of MD-2 with the
HTA125 mAb therefore demonstrates physical interaction
of MD-2 with TLR4. We used two different transfectants,
one of which expressed the flag epitope on both TLR4 and
MD-2 (Fig. 4 B, lanes 1 and 2). The other line, which had
the flag epitope on TLR4 but not on MD-2, was used as a
control (Fig. 4 B, lane 3). Precipitates were detected with
the anti-flag mAb. TLR4 was specifically precipitated from
either line (Fig. 4 B, lanes 2 and 3) with HTA125 as a 120-kD
band, which is consistent with a previous report (19). The
signal just below presumably represents an intracellular pre-
cursor. Another species of 
 
z
 
25–30 kD was detected from
Figure 1. The nucleotide sequence of human MD-2 and its similarity to
human MD-1. (A) The nucleotide sequence is shown with a deduced
amino acid sequence. The signal peptide and canonical N-glycosylation sites
are underlined. The stop codon is denoted by an asterisk. The nucleotide se-
quence of MD-2 will appear in the EMBL/GenBank/DDBJ nucleotide se-
quence databases under accession no. AB018549. (B) Amino acid sequences
of human MD-1 and MD-2 were aligned using the BLAST2 program at the
National Center for Biological Information (Bethesda, MD).
Figure 2. Expression of the MD-2 transcript. (A) To-
tal RNA (20 mg/lane) from the indicated human cell
lines was electrophoresed and hybridized with probes
for human MD-2, TLR4, and GAPDH as indicated.
Nalm-6, Ramos, Daudi, and RPMI8866 are of B lym-
phocyte lineage. CEM and Molt4 are of T cell origin.
U937 and THP-1 are of monocytic origin. K562 is the
erythroleukemia line. (B) Total RNA (20 mg/lane)
from the indicated mouse tissues was used for Northern
hybridization. The cDNA clone encoding mouse MD-2
was used as a probe. For GAPDH, the rat cDNA clone
was used. 
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the transfectant expressing MD-2 with the flag epitope
(Fig. 4 B, lane 2). The size is similar to that of MD-1 (24)
and is within a range expectable from the MD-2 amino acid
sequence, consisting of 160 amino acids with two 
 
N
 
-glyco-
sylation sites (Fig. 1 A). On the other hand, this signal was
not observed in the control precipitate, in which MD-2 did
not bear the flag epitope (Fig. 4 B, lane 3). MD-2 is thus
physically associated with TLR4.
We next explored a possible role for MD-2 in TLR4-
dependent signaling. As shown in Fig. 5, expression of
TLR4 alone conferred the triggering of NF-
 
k
 
B activation
in 293T cells, which confirmed previous reports (11, 19).
Interestingly, expression of MD-2 enhanced TLR4-depen-
dent activation of NF-
 
k
 
Bs by 2–3 fold. Transfection of
MD-1 with TLR4 did not have such an effect. Physical as-
sociation of MD-2 therefore influences the signaling via the
transmembrane TLR4 molecule. Preliminary studies sug-
gested that MD-2 forms a homodimer or a larger complex
on the cell surface. Such a complex may have multiple bind-
ing sites for TLR4 and facilitate cross-linking of TLR4,
leading to higher NF-
 
k
 
B activation. Further studies are un-
derway.
TLR4 may be an LPS receptor, as its gene is mutated in
low-responder mice C3H/HeJ and C57BL/10ScCr (12,
13). Transfection of TLR4, however, did not confer LPS
responsiveness on recipient cell lines (11), suggesting a re-
quirement for another molecule that linked TLR4 to LPS
signaling. We hypothesized that MD-2 might be such a
link, as it interacts with TLR4 and influences the signaling
of TLR4. To address this possibility, we studied LPS re-
sponsiveness of stable transfectants expressing TLR4 alone
or with MD-2 by measuring NF-
 
k
 
B activity (see Materials
and Methods). The stable transfectant line that expressed
TLR4 alone did not respond to LPS from 
 
Escherichia coli
 
0111:B4, 
 
E. coli 
 
055:B5 or 
 
Salmonella minnesota
 
 Re595 or
to lipid A (Fig. 6 A), which is consistent with the report by
Kirschning et al. (11). The Ba/F3 line, like the 293 cell line
(11), might lack a molecule indispensable for LPS signaling
Figure 3. Membrane anchoring of MD-2 via TLR4. A stable line ex-
pressing MD-2 with the flag epitope was stained with the anti-flag mAb,
followed by goat anti–mouse IgG–FITC (a and d). Staining with cell per-
meabilization is shown in d. Another stable transfectant was used that ex-
pressed MD-2 with the protein C epitope and TLR4 in b, c, and e. Cell
surface MD-2 and TLR4 are shown with the rat anti–protein C mAb or
the mouse anti–human TLR4 mAb HTA125 (b and c, respectively).
MD-2 expression in permeabilized cells is shown in e. The second re-
agents used were goat anti–rat IgG–PE or goat anti–mouse IgG–FITC,
respectively. Control histograms stained with isotype-matched mouse or
rat mAb are shown (dotted lines).
Figure 4. MD-2 is coprecipitated with
TLR4. (A) Stable transfectants expressing
MD-2 alone or with TLR4 were stained with
or without cell permeabilization. The intracel-
lular MD-2 precursor was stained with the
anti-protein C mAb. The specificity of the
anti-TLR4 mAb was shown by cell surface
staining of stable transfectants. Goat anti–
mouse IgG–FITC was used as the second re-
agent. Dotted lines correspond to histograms
stained with the second reagent alone. Panels
correspond to the original Ba/F3 line, a trans-
fectant expressing TLR4 alone, and a transfec-
tant expressing TLR4 1 MD-2, respectively.
(B) Stable transfectants expressing TLR4 and
MD-2 were subjected to immunoprecipitation with control mouse IgG (lane 1) or the anti-TLR4 mAb, HTA125 (lanes 2 and 3). After blotting, precip-
itated molecules were detected with an anti-flag mAb, M2. The precipitates shown in lanes 1 and 2 are from the transfectant expressing TLR4 and MD-2,
both of which were tagged with the flag epitope. In lane 3, we used the control line in which the flag epitope was on TLR4 but not on MD-2.
Figure 5. MD-2 enhances ligand-independent signaling via TLR4. A
human kidney cell line, 293T, was transfected with expression vectors
encoding the molecules indicated. A reporter plasmid for NF-kB activity
and an expression vector encoding b-galactosidase was also transfected
(see Materials and Methods). Relative NF-kB activity was calculated by
normalizing luciferase activity with b-galactosidase activity. Data are
shown as mean values from triplicate wells. Error bars, SD. 
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via TLR4. The mRNA of a candidate molecule MD-2 was
not expressed in either cell line (data not shown). The sta-
ble line expressing TLR4 and MD-2 was then examined.
Transfection of MD-2 conferred on the line strong NF-
 
k
 
B
responses to either LPS or lipid A at concentrations as low
as 0.1 ng/ml (Fig. 6 A). No response was observed to
detoxified LPS from which the fatty acid side chains of the
lipid A moiety were removed (data not shown). Receptor
activity acquired by introducing MD-2 was triggered
through TLR4, as the anti-TLR4 mAb HTA125 specifi-
cally inhibited the responses (Fig. 6 B). MD-2 thus confers
LPS signaling on TLR4.
We found, by reverse transcriptase (RT)-PCR expres-
sion of the transcript of TLR2, another LPS receptor in the
parental line Ba/F3. TLR3, TLR4, and TLR5 were not
detected by RT-PCR or Northern hybridization (data not
shown). In spite of the expression of the TLR2 transcript,
stable transfectants expressing the NF-
 
k
 
B reporter gene
alone (data not shown) or with TLR4 (Fig. 6 A) did not
show any significant LPS response. The amount of the cell
surface TLR2 protein, if any, may be too small to sense the
presence of LPS, or mouse TLR2 may not respond to LPS
as effectively as its human counterpart. Taken together
with specific inhibition with the anti-TLR4 mAb, LPS re-
sponses in stable transfectants expressing TLR4 and MD-2
are mediated by the cell surface complex of TLR4–MD-2
but not by TLR2. The TLR4–MD-2 receptor complex ef-
ficiently senses the presence of bacterial endotoxin.
CD14, another LRR molecule capable of binding to
 
LPS, is able to enhance LPS signaling via TLR2 (10, 11).
Mouse CD14 was not demonstrable by cell surface staining
of the Ba/F3 line (data not shown), but it is still possible
that soluble CD14 in FCS of culture medium contributes
to LPS signaling via TLR4–MD-2. Further study is of im-
portance and underway concerning a role of soluble and
membrane CD14 in LPS signaling of TLR4–MD-2.
Another finding with the new receptor complex TLR4–
MD-2 is that it has broader specificity than that recently
described for TLR2 (10). TLR2 recognizes the LPS from
 
S. minnesota
 
 Re595 much better than that from 
 
E. coli
 
055:B5. On the other hand, the TLR4–MD-2 complex re-
sponded equally to the two different types of LPS (Fig. 6 A).
LPS is a complex glycolipid composed of hydrophilic poly-
saccharides of the core and O-antigen structures, as well as a
hydrophobic domain called lipid A. Lipid A is a common
component, whereas considerable diversity of structure
is noted among the O-antigens. Because both TLR2 and
TLR4/MD-2 receptors responded well to lipid A (refer-
ence 10 and Fig. 6 A), the core and O-antigen from 
 
E. coli
 
055:B5 must selectively affect recognition by TLR2. Stud-
ies using stable transfectants expressing each TLR would
reveal further difference in recognition specificity of each
TLR. MD-2 might associate with other TLR family mem-
bers and confer the ability to respond to a broader spectrum
of pathogens, including gram-positive bacteria and fungi.
Such fundamental information concerning innate recogni-
tion of pathogens may also suggest new treatments for in-
fectious diseases and endotoxin shock.
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